Co Mary Dawn T, Orphin Laura, Cruz John, Pazoles Pamela, Green Karin M, Potts James, Leporati Anita M, Babon Jenny Aurielle B, Evans James E, Ennis Francis A, Terajima Masanori
Center for Infectious Disease and Vaccine Research, University of Massachusetts Medical School, Worcester, MA 01655, USA.
Vaccine. 2009 Jan 7;27(2):319-27. doi: 10.1016/j.vaccine.2008.09.092. Epub 2008 Oct 31.
We evaluated three commercial trivalent inactivated vaccines (TIVs) from the 2007-2008 season in terms of their ability to elicit in vitro T cell responses. T cell-mediated immunity may offer a more cross-reactive vaccine approach for the prevention of pandemic or epidemic influenza. Human cytotoxic T cell lines demonstrated differences in matrix protein 1 and nucleocapsid protein recognition of autologous target cells. Peripheral blood mononuclear cells stimulated with each of the TIVs showed statistically significant differences between the vaccines in the numbers of IFNgamma producing cells activated. These data suggest that TIV vaccines are not similar in their ability to activate human T cell responses.
我们评估了2007 - 2008年季节的三种商用三价灭活疫苗(TIV)引发体外T细胞反应的能力。T细胞介导的免疫可能为预防大流行或流行性流感提供一种更具交叉反应性的疫苗方法。人细胞毒性T细胞系在对自身靶细胞的基质蛋白1和核衣壳蛋白识别上表现出差异。用每种TIV刺激的外周血单个核细胞在激活的产生IFNγ的细胞数量上,疫苗之间显示出统计学上的显著差异。这些数据表明,TIV疫苗在激活人T细胞反应的能力方面并不相同。